Another hit piece on Ironwood, just before earnings call

This time, the author bashes Ironwood within a Synergy article.

Synergy Pharmaceuticals: Debt Vs. Equity Financing And The Concept Of Tradeoffs
Aug. 3, 2017 9:49 AM ET
|
20 comments
|
About: Synergy Pharmaceuticals, Inc. (SGYP), Includes: IRWD


Life Sciences Millennial

Research analyst, biotech, healthcare, small-cap

(499 followers)
Summary


Synergy finds themselves in the middle of the battle between debt vs. equity financing.

Trulance launch is continuing to impress and with roughly 32% refill rates, the company is surpassing Linzess' new 72mcg dose by 8-9% in refills.

Synergy is using a conservative approach in terms of recognizing revenue, and have over $4 million in deferred revenue from Q1 2017, which should bring confidence ahead of earnings call.

By not taking the debt financing route, Synergy will be profitable this time next year, while Ironwood remains unprofitable after five years and with $238 million remaining in convertible debt.

Debt financing could put Synergy in a bad position as far as interest rates, and a favorable merger, if it were to happen.

 

Pretty sure after today's call, Ironwood will be 'refluxing' into a Sea of Red again!

 

Can't turn a profit, Linzess Sales in the toilet..growth is over

 

SGYP under $3, ouch!